(Reuters) – Moderna shares fell 6% on Friday after a longer-term analysis of a trial indicated a quicker fall in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine.
At least two analysts pointed to the data, posted ahead of a conference on RSV next week, that showed a vaccine efficacy of about 63% after 8.6 months, from 84% at 3.3 months.
Pfizer’s vaccine efficacy went from 67% to 49% in 17 months, while GSK’s fell to 77% at 14 months from 83%, TD Cowen analyst Tyler Van Buren said.
The data suggests Moderna’s RSV vaccine efficacy is “declining quicker than the GSK and Pfizer vaccines,” he said.
Moderna’s shares were at $88 in morning trading, and were on track for their biggest one-day fall since November.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
